Cite
HARVARD Citation
Jaderberg, M. et al. (n.d.). 361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes. Journal for immunotherapy of cancer. pp. A220-A221. [Online].